# Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects

> **NCT00956449** · PHASE2 · COMPLETED · sponsor: **Novartis** · enrollment: 126 (actual)

## Conditions studied

- Influenza
- Seasonal Influenza

## Interventions

- **BIOLOGICAL:** Seasonal Influenza Vaccine

## Key facts

- **NCT ID:** NCT00956449
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2017-03-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00956449

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00956449, "Safety and Immunogenicity of Influenza Vaccine (Surface Antigen, Inactivated) [Ph.Eur], Formulation 2009-2010, When Administered to Non-Elderly Adult and Elderly Subjects". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00956449. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*